AxoGen, Inc.

NASDAQ:AXGN

Medical - Devices

Healthcare
$56.95 +0.56%

+$0.25 today

Market cap
$3.40B
Beta
1.12
P/E (TTM)
-73.4
EPS (TTM)
-$0.61
52W Low $9.35High $45.83

Volume 2.11M

Average 1.08M

AXGN Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

AxoGen, Inc.NASDAQ: AXGN

Net Change in Cash · Q3 FY2026 · quarter ended Sep 2026

Net change in cash growth accelerates

Q3 FY2026 net change in cash of $234.32M rose 12457.1% year over year, ahead of the +8968.7% change in trailing-twelve-month net change in cash. Sequentially, it rose 8398.9% from the prior quarter.

Context

  • Net change in cash amounted to 2.7% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +12457.1% holds above the trailing-twelve-month pace of +8968.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$234.32M+8398.9% QoQ
Last fiscal yearDec 2025
$5.99M+272.6% YoY
LTMSep 2026
$293.83M+8968.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12457.1%——
1 year+272.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
5.99M USD
Year-over-year change
+272.6%

Net Change in Cash vs competitors

How AXGN compares with its peers on the latest reported figures

  • AXGN's LTM Sep 2026 net change in cash of $293.83M is the largest of the 7 companies compared; the peer median is $10.87M.
  • Its year-over-year change of +8968.7% is the highest of 7, against a peer median of -81.1%.
  • Net change in cash amounts to 110.1% of revenue for AXGN, versus a peer median of 5.8%.
AXGN Competitors Peer median
Net Change in Cash for AXGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AXGNAxoGen, Inc.LTM Sep 2026$293.83M +8968.7%—110.1%
HUMAHumacyte, Inc.LTM Mar 2026$64.45M +2324.8%-13.1%3197.0%
MDXGMiMedx Group, Inc.LTM Mar 2026$53.34M -7.9%—13.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$18.44M -187.0%+55.0%3.6%
BSEMBioStem Technologies, Inc.LTM Jun 2026$17.14M -170.6%+149.6%—
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$6.72M +728.9%+73.7%5.5%
TELATELA Bio, Inc.LTM Jun 2026$4.6M -154.3%-1.3%5.8%
Peer median (excluding AXGN) $10.87M-81.1%+55.0%5.8%

Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.99M)(28.95M)(21.72M)(9.96M)(15.7M)
Depreciation & Amortization4.74M4.85M5.55M7.84M8.19M
Deferred Income Tax3.37M0000
Stock-Based Compensation10.92M15.59M14.42M15.91M30.11M
Change in Working Capital(6.28M)(9.56M)(4.39M)(10.04M)(24.62M)
Accounts Receivables(499K)(4.64M)(2.69M)392K(2.46M)
Inventory(7.48M)(3.66M)(6.05M)(10.16M)(9.19M)
Accounts Payables(270K)660K6.51M125K(7.16M)
Other Working Capital1.97M(1.93M)(2.15M)(399K)(5.81M)
Other Non-Cash Items831K2M415K797K2.83M
Operating Cash Flow(13.41M)(16.07M)(5.72M)4.54M812K
Capital Expenditures(28.4M)(21.25M)(14.92M)(4.52M)(3.75M)
Acquisitions (Net)(589K)3.2M000
Purchases of Investments(68.7M)(39.25M)(10.2M)(5.77M)(13.72M)
Sales of Investments72.5M57.3M44.37M014M
Other Investing Activities1.54M(3.2M)(1.05M)(1.42M)(1.85M)
Investing Cash Flow(23.65M)(3.2M)19.25M(10.3M)(5.32M)
Debt Repayment14.99M(12K)(10K)(10K)(32K)
Common Stock Issued5.47M1.81M1.96M2.3M10.53M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow20.45M1.79M1.95M2.29M10.5M
Effect of Forex Changes00000
Net Change in Cash(16.6M)(17.47M)15.49M(3.47M)5.99M
Free Cash Flow(41.81M)(37.32M)(20.63M)11K(2.93M)

AxoGen, Inc.

NASDAQ:AXGN

Intrinsic Alpha fair value

Locked

Current Price

$56.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.